The company plans to monetize through partnerships, usage fees, and revenue sharing. It may collaborate with pharmaceutical companies to incorporate ESM3 into their workflows or share revenue with researchers for commercialized breakthrough discoveries using ESM3. The company will soon offer ESM3 and its derivatives to select AWS customers via AWS’ SageMaker AI dev platform, Bedrock AI platform, and HealthOmics service. ESM3 will also be available to select customers using NVIDIA’s NIM microservices.
Key takeaways:
- EvolutionaryScale, a startup focused on building AI models for generating novel proteins, has raised $142 million in a seed round led by ex-GitHub CEO Nat Friedman, Daniel Gross and Lux Capital, with participation from Amazon and NVentures, Nvidia’s corporate venture arm.
- The company has developed ESM3, an AI model that can create proteins for use in drug discovery and materials science. The model was trained on a dataset of 2.78 billion proteins.
- EvolutionaryScale plans to monetize through partnerships, usage fees, and revenue sharing. It might work with pharmaceutical companies to integrate ESM3 into their workflows or share revenue with researchers for commercialized discoveries using ESM3.
- The company is planning to bring ESM3 and its derivatives to select AWS customers via AWS’ SageMaker AI dev platform, Bedrock AI platform and HealthOmics service, and to select customers using NVIDIA’s NIM microservices.